Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.55 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.55 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 6/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.55 |
| ▸ | BRAF | P15056 | 5/20 | 0.55 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | GLA | P06280 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12461169 | 0.87 | MAPK14 (0.57) | MAPK14CSNK1DCSNK1ERAF1MAPK13 | |
| SCHEMBL12461181 | 0.87 | TGFBR1 (0.53) | MAPK14CSNK1DCSNK1ERAF1MAPK13 | |
| SCHEMBL12461174 | 0.87 | MAPK14 (0.58) | MAPK14CSNK1DCSNK1ERAF1MAPK13 | |
| SCHEMBL2148151 | 0.85 | MAPK14 (0.68) | MAPK14CSNK1DCSNK1ERAF1MAPK13 | |
| SCHEMBL12461178 | 0.84 | BRAF (0.59) | MAPK14CSNK1DCSNK1ERAF1BRAF | |
| SCHEMBL12461201 | 0.84 | KDM4E (0.52) | MAPK14CSNK1DCSNK1ERAF1MAPK13 | |
| SCHEMBL12461176 | 0.84 | BRAF (0.51) | MAPK14CSNK1DCSNK1ERAF1MAPK13 | |
| SCHEMBL12461175 | 0.84 | TGFBR1 (0.49) | MAPK14CSNK1DCSNK1ERAF1MAPK13 | |
| SCHEMBL12461153 | 0.82 | BRAF (0.59) | MAPK14CSNK1DCSNK1ERAF1MAPK13 | |
| SCHEMBL2148588 | 0.82 | BRAF (0.59) | MAPK14CSNK1DCSNK1ERAF1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| WO-2011085269-A1 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040983-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPK14 193/4885CSNK1D 531/4885CSNK1E 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.